Stratasys and CollPlant Unite Technologies to Transform Healthcare with IndustrialScale Bioprinting of Tissues and Organs

EDEN PRAIRIE, Minn. & REHOVOT, Israel–(BUSINESS WIRE)–Apr 4, 2023– Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant’s regenerative breast implants program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230404005729/en/ Human size breast implant, printed with Stratasys P3 3D printing technology and CollPlant’s bioink. (Photo: Business Wire) Stratasys is a leader in polymer…